1. Home
  2. IFRX vs ATLO Comparison

IFRX vs ATLO Comparison

Compare IFRX & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • ATLO
  • Stock Information
  • Founded
  • IFRX 2007
  • ATLO 1903
  • Country
  • IFRX Germany
  • ATLO United States
  • Employees
  • IFRX N/A
  • ATLO N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • IFRX Health Care
  • ATLO Finance
  • Exchange
  • IFRX Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • IFRX 143.7M
  • ATLO 144.8M
  • IPO Year
  • IFRX 2017
  • ATLO N/A
  • Fundamental
  • Price
  • IFRX $2.24
  • ATLO $16.44
  • Analyst Decision
  • IFRX Strong Buy
  • ATLO
  • Analyst Count
  • IFRX 1
  • ATLO 0
  • Target Price
  • IFRX $8.00
  • ATLO N/A
  • AVG Volume (30 Days)
  • IFRX 401.6K
  • ATLO 24.2K
  • Earning Date
  • IFRX 11-08-2024
  • ATLO 01-17-2025
  • Dividend Yield
  • IFRX N/A
  • ATLO 6.14%
  • EPS Growth
  • IFRX N/A
  • ATLO N/A
  • EPS
  • IFRX N/A
  • ATLO 0.98
  • Revenue
  • IFRX $187,930.00
  • ATLO $51,071,000.00
  • Revenue This Year
  • IFRX $435.15
  • ATLO N/A
  • Revenue Next Year
  • IFRX $180.44
  • ATLO N/A
  • P/E Ratio
  • IFRX N/A
  • ATLO $16.72
  • Revenue Growth
  • IFRX 177.12
  • ATLO N/A
  • 52 Week Low
  • IFRX $1.17
  • ATLO $15.69
  • 52 Week High
  • IFRX $2.82
  • ATLO $22.41
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 52.76
  • ATLO 40.42
  • Support Level
  • IFRX $1.93
  • ATLO $17.13
  • Resistance Level
  • IFRX $2.74
  • ATLO $16.98
  • Average True Range (ATR)
  • IFRX 0.25
  • ATLO 0.46
  • MACD
  • IFRX -0.06
  • ATLO -0.09
  • Stochastic Oscillator
  • IFRX 34.88
  • ATLO 35.56

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.

Share on Social Networks: